{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:30:13Z","timestamp":1792884613373,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"DOI":"10.13039\/100011957","name":"Takeda Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several studies have suggested that chemotherapy-free regimens consisting of blinatumomab and a BCR::ABL1 tyrosine kinase inhibitor are highly effective in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL). However, the clinical and molecular characteristics that predict for relapse with these chemotherapy-free regimens are largely unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective phase II clinical trial of the combination of blinatumomab and ponatinib in 76 patients with newly diagnosed Ph\u2009+\u2009ALL. Patients received 12\u201315 doses of intrathecal chemotherapy as central nervous systemic (CNS) prophylaxis. The patterns of relapse and the clinical and molecular predictors of relapse were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      With a median follow-up of 29 months, the estimated 3-year event-free survival rate was 78% and the 3-year overall survival rate was 88%. Ten patients (13%) relapsed, with a median time to relapse of 18 months (range, 8\u201324 months). Six relapses occurred only in extramedullary sites (CNS,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095; peritoneum and lymph nodes,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). CD19 expression remained high at relapse in all patients. On univariate analysis, factors associated with an increased risk of relapse were: white blood cell (WBC)\u2009\u2265\u200970\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L at diagnosis (sHR 8.86 [95% CI 2.33\u201333.70];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001), CNS involvement at diagnosis (sHR 6.87 [95% CI 1.54\u201330.68];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01), and\n                      <jats:italic>VPREB1<\/jats:italic>\n                      deletion (sHR 4.06 [95% CI 1.05\u201315.76];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04). WBC\u2009\u2265\u200970\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L was present in 22% of the cohort and was associated with a 53% cumulative incidence of relapse (CIR), as compared with a CIR rate of 6% for patients with WBC\u2009&lt;\u200970\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L. Neither\n                      <jats:italic>IKZF1<\/jats:italic>\n                      <jats:sup>plus<\/jats:sup>\n                      genotype,\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      transcript type, nor measurable residual disease kinetics by next-generation sequencing for IG\/TR rearrangements significantly impacted the risk of relapse. High WBC at diagnosis was the only variable significantly associated with relapse on multivariate analysis (sHR 16.29 [95% CI 2.35\u2013113.00;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      WBC\u2009\u2265\u200970\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L is a high-risk feature in patients with Ph\u2009+\u2009ALL receiving frontline blinatumomab and ponatinib and may supersede the prognostic importance of baseline molecular features. Alternative frontline treatment strategies may be needed for these patients to reduce the risk of relapse and improve long-term outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT03263572).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-025-01709-y","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:27:06Z","timestamp":1747225626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Molecular characterization and predictors of relapse in patients with Ph\u2009+\u2009ALL after frontline ponatinib and blinatumomab"],"prefix":"10.1186","volume":"18","author":[{"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Furudate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Karrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Garris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"1709_CR1","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMra2113347","volume":"386","author":"R Fo\u00e0","year":"2022","unstructured":"Fo\u00e0 R, Chiaretti S. Philadelphia Chromosome-Positive acute lymphoblastic leukemia. N Engl J Med. 2022;386:2399\u2013411.","journal-title":"N Engl J Med"},{"key":"1709_CR2","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, et al. Long-Term results of the Dasatinib-Blinatumomab protocol for adult Philadelphia-Positive ALL. J Clin Oncol. 2024;42:881\u20135.","journal-title":"J Clin Oncol"},{"key":"1709_CR3","unstructured":"Kantarjian H, Short NJ, Haddad FG et al. Results of the simultaneous combination of Ponatinib and blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol 0:JCO.24.00272."},{"key":"1709_CR4","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e24\u201334.","journal-title":"Lancet Haematol"},{"key":"1709_CR5","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","volume":"6","author":"NJ Short","year":"2019","unstructured":"Short NJ, Kantarjian HM, Loghavi S, et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019;6:e29\u201337.","journal-title":"Lancet Haematol"},{"key":"1709_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3324\/haematol.2013.093765","volume":"99","author":"R Luthra","year":"2014","unstructured":"Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using miseq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99:465\u201373.","journal-title":"Haematologica"},{"key":"1709_CR7","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41.","journal-title":"Genome Biol"},{"key":"1709_CR8","doi-asserted-by":"crossref","unstructured":"Daenekas B, P\u00e9rez E, Boniolo F et al. Conumee 2.0: enhanced copy-number variation analysis from DNA methylation arrays for humans and mice. Bioinformatics 40, 2024.","DOI":"10.1093\/bioinformatics\/btae029"},{"key":"1709_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470\u201380.","journal-title":"N Engl J Med"},{"key":"1709_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajh.24625","volume":"92","author":"NJ Short","year":"2017","unstructured":"Short NJ, Kantarjian HM, Sasaki K, et al. Poor outcomes associated with +\u2009der(22)t(9;22) and\u2013\u20099\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017;92:238\u201343.","journal-title":"Am J Hematol"},{"key":"1709_CR11","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","volume":"106","author":"S Chiaretti","year":"2021","unstructured":"Chiaretti S, Ansuinelli M, Vitale A, et al. A multicenter total therapy strategy for de Novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. Haematologica. 2021;106:1828\u201338.","journal-title":"Haematologica"},{"key":"1709_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128:504\u20137.","journal-title":"Blood"},{"key":"1709_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11912-022-01220-4","volume":"24","author":"S Paul","year":"2022","unstructured":"Paul S, Short NJ. Central nervous system involvement in adults with acute leukemia: diagnosis, prevention, and management. Curr Oncol Rep. 2022;24:427\u201336.","journal-title":"Curr Oncol Rep"},{"key":"1709_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.26816","volume":"98","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, Short NJ, Jain N, et al. Frontline combination of Ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023;98:493\u2013501.","journal-title":"Am J Hematol"},{"key":"1709_CR15","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1182\/blood.2023023502","volume":"143","author":"Y Chalandon","year":"2024","unstructured":"Chalandon Y, Rousselot P, Chevret S, et al. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia. Blood. 2024;143:2363\u201372.","journal-title":"Blood"},{"key":"1709_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood-2024-207892","volume":"144","author":"S Chiaretti","year":"2024","unstructured":"Chiaretti S, Leoncin M, Elia L, et al. Efficacy and toxicity of frontline Ponatinib plus blinatumomab for adult Ph\u2009+\u2009ALL patients of all ages. Intermediate analysis of the Gimema ALL2820. Blood. 2024;144:835\u2013835.","journal-title":"Blood"},{"key":"1709_CR17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41375-021-01496-8","volume":"36","author":"Y Sasaki","year":"2022","unstructured":"Sasaki Y, Kantarjian HM, Short NJ, et al. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or Ponatinib. Leukemia. 2022;36:1253\u201360.","journal-title":"Leukemia"},{"key":"1709_CR18","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: A Meta-analysis. JAMA Oncol. 2017;3:e170580\u2013170580.","journal-title":"JAMA Oncol"},{"key":"1709_CR19","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/ajh.26949","volume":"98","author":"NJ Short","year":"2023","unstructured":"Short NJ, Jabbour E, Macaron W, et al. Ultrasensitive NGS MRD assessment in Ph\u2009+\u2009ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023;98:1196\u2013203.","journal-title":"Am J Hematol"},{"key":"1709_CR20","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","volume":"36","author":"J Zuna","year":"2022","unstructured":"Zuna J, Hovorkova L, Krotka J, et al. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia. 2022;36:2793\u2013801.","journal-title":"Leukemia"},{"key":"1709_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/B978-0-12-800267-4.00004-3","volume":"122","author":"M Reth","year":"2014","unstructured":"Reth M, Nielsen P. Signaling circuits in early B-cell development. Adv Immunol. 2014;122:129\u201375.","journal-title":"Adv Immunol"},{"key":"1709_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/leu.2013.223","volume":"28","author":"DS Mangum","year":"2014","unstructured":"Mangum DS, Downie J, Mason CC, et al. VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia. 2014;28:216\u201320.","journal-title":"Leukemia"},{"key":"1709_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.V116.21.273.273","volume":"116","author":"RR Miles","year":"2010","unstructured":"Miles RR, Downie J, Jahromi MS, et al. VPREB1 deletions occur independent of Lambda-Light chain rearrangement and predict worse outcome in pediatric acute lymphoblastic leukemia (ALL). Blood. 2010;116:273\u2013273.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01709-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:27:07Z","timestamp":1747225627000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01709-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1709"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01709-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and in compliance with good clinical practice guidelines and applicable laws. The protocol was approved by the institutional review boards or ethics committee at study sites. Written informed consent was obtained before study entry from each patient or from the patient\u2019s legally authorized representative if the patient was unable to provide consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.J.S. has received consulting fees from Pfizer Inc., GlaxoSmithKline, NKARTA, Autolus and Sanofi, research funding from Takeda Oncology, Astellas Pharma Inc., Xencor, Stemline Therapeutics and NextCure and honoraria from Adaptive Biotechnologies, Novartis, Amgen, Takeda Oncology, Pfizer Inc., Astellas Pharma Inc., Sanofi and BeiGene. N.J. has received consulting fees from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies, Kite\/Gilead, Precision Biosciences, Beigene, Cellectis, MEI Pharma, Ipsen, CareDX, MingSight, Autolus, Novalgen, and research funding from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Kite\/Gilead, Mingsight, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave, Novartis, Carna Biosciences, Sana Biotechnology, Kisoji Biotechnology. H.K. has received research funding from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, and Novartis and honoraria from AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline and Takeda Oncology. E.J. has received consulting fees and research funding from Abbvie, Adaptive biotechnologies, Amgen, Ascentage, ASTX, Astra-Zeneca, Autolus, BMS, Genentech, Hikma, Kite, Novartis, Pfizer, Takeda Oncology and Jazz. S.L. has received consulting fees Servier, Daiichi Sankyo, Syndax, Tempus AI, Kura oncology, Abbvie, and research funding from Amgen and Astellas. The other authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}